Hämoblastosen

Titel
Studie
Jahr

Treatment of patients with multiple myeloma selected for high-dose chemotherapy and autologous stem cell transplantation – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Tamm, I., Anhuf, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P608), 178.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2017

German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

IDELA
2017

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial.

Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer, N., Ruefer, A., Ziske, C., Knauf, W., Cathomas, R., von Moos, R., Hitz, F., Sauter, R., Hiendlmeyer, E., Cantoni, N., Bargetzi, M., Driessen, C., 2016.

Br. J. Haematol. 176(5), 770–782. doi:10.1111/bjh.14481

Indikation: Hämoblastosen; Veranstaltung: -; Journal: British Journal of Hematology

BRd
2016

1st -line treatment of patients with mantle cell lymphoma: Treatment reality and first outcome data from the German prospective TLN Registry.

Knauf, W., Bertram, Fietz, T., Kirste, T., Grugel, R., Schnitzler, Abenhardt, W., 2016.

Oncol Res Treat 39 (suppl 3)(V364), 120. doi:10.1159/000449050

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2016

Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with Non-Hodgkin-Lymphoma (NHL): results from an interim analysis of the non-interventional study NADIR.

Fietz, T., Wolff, T., Schulz, H., Sandner, R., Reichert, D., Hurtz, H.-J., Müller, J., Grebhardt, S., 2016.

Oncol Res Treat, DGHO-Jahrestagung (Leipzig) 39 (suppl3)(P950), 292. doi:10.1159/000449050

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NADIR
2016

Piaza: Non-interventional Study on Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMML (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder).

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Neidig, C., Teichmann, B., Harde, J., Trarbach, T., 2015.

Oncol Res Treat 38 (suppl.5)(P235), 70. doi:10.1159/000439070

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PIAZA
2015

Revlimid-NIS: Non-interventional study on therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone

Knauf, W., Aldaoud, A., Maintz, C., Groschek, M., Teichmann, B., Harde, J., Trarbach Tanja, 2015.

Oncol Res Treat 38 (suppl.5)(P783), 238. doi:10.1159/000439070

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

Revlimid-NIS
2015

1st-line treatment of patients with high-grade non-Hodgkin’s lymphoma: Similar effectiveness with R-CHOP-14 or R-CHOP-21 – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Mohm, J., Rauh, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2015.

Oncol Res Treat 38 (suppl 5)(V75), 19. doi:10.1159/000439070

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2015

Prophylactic treatment of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with NHL: Subgroup analysis of the non-interventional study NADIR

Fietz, T., Wolff, T., Sandner, R., Janssen, J., Hurzt, H.-J., Heits, F., Weide, R., Weißenborn, G., Losem, C., Lück, A., Kurbacher, C., Teichmann, B., Harde, J., Scheuerlein, R., 2015.

Oncol Res Treat 38 (suppl.5)(P256), 78 doi:10.1159/000439070

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

NADIR
2015

Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Frank, M., Straßl, L., 2015.

Ann Hematol 94, 1553–1558. doi:10.1007/s00277-015-2404-1

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Annals of Hematology

Be-1st
2015

1st-line treatment with R-CHOP-14 or R-CHOP-21 in patients with high-grade non-Hodgkin’s lymphoma is similarly effective: Date from the German prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Mohm, J., Rauh, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2014.

Blood 124(21), 4406.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2014

Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.

Knauf, W., Abenhardt, W., Dörfel, S., Meyer, D., Grugel, R., Münz, M., Hartmann, H., Marschner, N., 2014.

Hematol Oncol. doi:10.1002/hon.2139

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Hematological Oncology

TLN
2014

Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany–data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).

Knauf, W., Abenhardt, W., Aldaoud, A., Nusch, A., Grugel, R., Münz, M., Hartmann, H., Marschner, N., TLN Study Group, 2014.

Oncol Res Treat 37, 635–644. doi:10.1159/000368315

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Oncology Research and Treatment

TLN
2014

Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st.

Bruch, H.-R., Aldaoud, A., Klausmann, M., Hansen, R., Losem, C., Frank, M., Straßl, L., Ruffert, K., 2014.

Haematologica 99 (suppl 1) (PB1504).

Indikation: Hämoblastosen; Veranstaltung: EHA; Journal: Haematologica

Be-Cell-1st
2014

1st-line treatment with BR and FCR in patients with chronic lymphocytic leukamia.

Knauf, W., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2014.

Oncol Res Treat 37 (suppl5)(P186), 50. doi:10.1159/000368945

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2014

Multiple myeloma and neurotoxicity: Patient-reported and physician-recorded findings from the German prospective TLN Registry and the LyTox project.

Hurtz, H.-J., Knauf, W., Hutzschenreuter, U., Mittermüller, J., Grugel, R., Harde, J., Boller, E., Hartmann, H., Marschner, N., 2014.

Oncol Res Treat 37 (suppl 5)(P861), 286–287. doi:10.1159/000368945

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2014

Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in routine clinical practice: Interim analysis of the German non-interventional study Be-CeLL1st.

Bruch, H.-R., Aldaoud, A., Klausmann, M., Hansen, R., Losem, C., Frank, M., Straßl, L., Ruffert, K., 2014.

Haematologica 99 (suppl 1) (PB1504).

Indikation: Hämoblastosen; Veranstaltung: EHA; Journal: Haematologica

Be-Cell-1st
2014

Bendamustine-based first line therapy in chronic lymphocytic leukemia (CLL) in treatment routine: Interim results of the non-interventional study Be-CeLL1st.

Ruffert, K., Aldaoud, A., Klausmann, M., Bruch, H.-R., Hansen, R., Losem, C., Frank, M., Straßl, L., 2014.

Oncol Res Treat 37(suppl 5)(P194), 53–54. doi:10.1159/000368945

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

Be-Cell-1st
2014

Efficacy and Safety of Azacitidine (Vidaza®) in Patients with Myelodysplastic Syndromes (MDS, Int-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder): First interim analysis of the non-interventional study PIAZA.

Wehmeyer, J., Zaiss, M., Losem, C., Schmitz, S., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P797), 241. doi:10.1159/000356365

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

PIAZA
2013

Response to 1st-line Treatment with BR or R-CHOP in Patients with Indolent non-Hodgkin’s Lymphoma: First Outcome Data from the German Prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Hansen, R., Grugel, R., Harde, J., Marschner, N., 2013.

Blood 122(21), 3036.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2013

Response to 1st-line Treatment with BR or FCR in Patients with Chronic Lymphocytic Leukaemia: First Outcome Data from the German Prospective TLN Registry.

Knauf, W.U., Abenhardt, W., Engel, E., Grugel, R., Harde, J., Marschner, N., 2013.

Blood 122(21), 4181.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2013

Therapy of relapsed/ refractory multiple myeloma with a combination of Lenalidomide plus Dexamethasone: First interim analysis of the non-interventional study “Revlimid.”

Knauf, W., Aldaoud, A., Groschek, M., Teichmann, B., Harde, J., Hasskarl, J., 2013.

Onkologie 36 (suppl. 7)(P532), 155. doi:10.1159/000356365

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

Revlimid-NIS
2013

Treatment of indolent NHL by office-based haematologists in Germany: R-bendmustine replaces R-CHOP as “Standard of Care.”

Knauf, W., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2013.

Hematol Oncol 31 (Suppl. I)(Abstract 467), 248. doi:10.1002/hon.2059

Indikation: Hämoblastosen; Veranstaltung: ICML; Journal: Hematological Oncology

TLN
2013

Treatment of Elderly Patients with CLL: Does Bendamustine Replace Chlorambucil as “Standard of Care”?

Knauf, W., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2013.

Hematol Oncol 31 (Suppl. I)(Abstract 372), 219. doi:10.1002/hon.2059

Indikation: Hämoblastosen; Veranstaltung: ICML; Journal: Hematological Oncology

TLN
2013

VMP in 1st-Line Treatment of Non-Transplant Patients with Multiple Myeloma in Routine Practice: First Follow-Up Data from the Tumour Registry Lymphatic Neoplasms.

Knauf, W., Abenhardt, W., Harich, H.-D., Schlag, R., Grugel, R., Marschner, N., 2013.

Onkologie 36 (suppl 7)(P528), 152–153. doi:10.1159/000356365

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

TLN
2013

Non-interventional study Be-1st: First line therapy with bendamustine in advanced indolent non-Hodgkin lymphoma (NHL) in treatment routine.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Bruch, H.-R., Straßl, L., 2013.

haematologica, EHA (Stockholm) 98, P321.

Indikation: Hämoblastosen; Veranstaltung: EHA; Journal: Haematologica

Be-1st
2013

Bendamustine-Rituximab (BR) Replaces R-CHOP As “Standard of Care” in the Treatment of Indolent Non-Hodgkin Lymphoma in German Hematology Outpatient Centres.

Knauf, W.U., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012.

Blood 120(21), 3666.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2012

Bendamustine Replaces Chlorambucil As “Standard of Care” in the Treatment of Elderly Patients with Chronic Lymphocytic Leukemia in German Hematology Outpatient Centres.

Knauf, W.U., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012.

Blood 120(21), 4605.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2012

Changes in German oncology outpatient centres of indolent non-Hodgkin lymphoma and chronic lymphocytic leukaemia in German haematology outpatient centres: Data from the clinical TLN Registry.

Knauf, W., Abenhardt, W., Nusch, A., Grugel, R., Marschner, N., 2012.

Onkologie 35 (suppl 6)(P724), 217. doi:10.1159/000178474

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

TLN
2012

TLN
2011

TLN
2011

How to Treat Chronic Lymphocytic Leukemia? Data From a Clinical Registry by Office-Based Hematologists in Germany (TLN Registry).

Knauf, W., Abenhardt, W., Aldaoud, A., Lerchenmuller, C., Koska, M., Marschner, N., 2011.

Blood 118(21), 4606.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

TLN
2011

Age-dependent differences in treatment of patients with Multiple Myeloma and Chronic Lymphocytic Leukaemia in outpatient cancer centres in Germany. Data from a clinical registry – TLN Registry.

Knauf, W., Abenhardt, W., Aldaoud, A., Lerchenmüller, C., Koska, M., Marschner, N., 2011.

Onkologie 34 (suppl 6)(V118), 21. doi:10.1159/000333299

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

TLN
2011

Treatment of patients with Multiple Myeloma Routine treatment by office-based haematologists in Germany – Data from the Tumour Registry Lymphatic Neoplasms.

Hartmann, H., Knauf, W., Abenhardt, W., Aldaoud, A., Lerchenmüller, C., Koska, M., 2011.

ISPOR 14th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Hämoblastosen; Veranstaltung: ISPOR; Journal: -

TLN
2011

First line therapy with Bendamustine in advanced indolent Non-Hodgkin Lymphoma in treatment routine – interim analysis of the non-interventional study Be-1st.

Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Grass, J., Straßl, L., 2011.

Onkologie 34 (suppl.6)(P891), 268. doi:10.1159/000333305

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

Be-1st
2011

Tumorregister Lymphatische Neoplasien (TLN) der niedergelassenen Hämato-/Onkologen in Deutschland.

Abenhardt, W., Knauf, W., 2011.

Indikation: Hämoblastosen; Veranstaltung: Lymphom-Meeting; Journal: -

TLN
2011

Treatment of patients with lymphatic B-cell neoplasia (TLN-Registry): A “Real Life” treatment overview in outpatient, office-based cancer centres in Germany.

Knauf, W., Abenhardt, W., Aldaoud, A., Nacak, T., 2010.

Onkologie 33 (suppl 6)(V366), 132. doi:10.1159/000321410

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Onkologie

TLN
2010

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.-J., Huguet, F., Del Giudice, I., Klein, P., Tremmel, L., Merkle, K., Montillo, M., 2009.

J Clin Oncol 27, 4378–4384. doi:10.1200/JCO.2008.20.8389

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Journal of Clinical Oncology

02 CLL III
2009

Bendamustine in the treatment of chronic lymphocytic leukemia.

Knauf, W., 2009

Expert Rev Anticancer Ther 9, 165–174. doi:10.1586/14737140.9.2.165

Indikation: Hämoblastosen; Veranstaltung: -; Journal: Expert Review of Anticancer Therapy

02 CLL III
2009

Bendamustine versus chlorambucil as first-line treatment in B cell chronic lymphocytic leukemia: An updated analysis from an international phase III study.

Knauf, W.U., Lissitchkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Hoeffken, K., Huguet, F., Foa, R., Merkle, K., Montillo, M., 2008.

Blood 112(11), 2091.

Indikation: Hämoblastosen; Veranstaltung: ASH; Journal: Blood

02 CLL III
2008

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com